VIPER-SHOCK

VIPER-SHOCK

VIPER-SHOCK is a randomized, double-blind, clinical trial in 40 evaluable patients with septic shock investigating the effect of a plasma product (OCTAPLAS) vs. crystalloid as volume resuscitation during the acute phase. The primary endpoint is functional capillary density after 24 hours measured by MicroVision sublingually. The study is conducted in a collaboration with the Intensive Care Unit at Bispebjerg Hospital and dr. Niels Erisktrup Clausen is the primary investigator.